Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Transplantation Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.
Department of Internal Medicine, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.
Int J Mol Sci. 2024 Jul 5;25(13):7396. doi: 10.3390/ijms25137396.
Sepsis poses a significant threat to human health due to its high morbidity and mortality rates worldwide. Traditional diagnostic methods for identifying sepsis or its causative organisms are time-consuming and contribute to a high mortality rate. Biomarkers have been developed to overcome these limitations and are currently used for sepsis diagnosis, prognosis prediction, and treatment response assessment. Over the past few decades, more than 250 biomarkers have been identified, a few of which have been used in clinical decision-making. Consistent with the limitations of diagnosing sepsis, there is currently no specific treatment for sepsis. Currently, the general treatment for sepsis is conservative and includes timely antibiotic use and hemodynamic support. When planning sepsis-specific treatment, it is important to select the most suitable patient, considering the heterogeneous nature of sepsis. This comprehensive review summarizes current and evolving biomarkers and therapeutic approaches for sepsis.
脓毒症因其在全球范围内的高发病率和死亡率，对人类健康构成了重大威胁。传统的鉴定脓毒症或其病原体的诊断方法既耗时又导致高死亡率。生物标志物的发展克服了这些限制，目前用于脓毒症的诊断、预后预测和治疗反应评估。在过去的几十年中，已经确定了超过 250 种生物标志物，其中一些已用于临床决策。与脓毒症诊断的局限性一致，目前尚无针对脓毒症的特定治疗方法。目前，脓毒症的一般治疗方法是保守治疗，包括及时使用抗生素和血流动力学支持。在制定脓毒症特异性治疗方案时，重要的是要考虑到脓毒症的异质性，选择最合适的患者。这篇全面的综述总结了当前和正在发展的脓毒症的生物标志物和治疗方法。
